Corbus Pharmaceuticals Holding

$8.21

(as of Jun 20, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Corbus Pharmaceuticals Holding

Stock Price

$8.21

Ticker Symbol

CRBP

Exchange

NASDAQ

Industry Information for Corbus Pharmaceuticals Holding

Sector

Healthcare

Industry

Biotechnology

Company Description for Corbus Pharmaceuticals Holding

Website

https://www.corbuspharma.com

Country

USA

Full Time Employees

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Fundamentals for Corbus Pharmaceuticals Holding

Market Capitalization

$101,687,816

EBITDA

$-57,240,000

Dividends per Share

P/E Ratio

Forward P/E Ratio

Earnings per Share

$-4.24

Earnings per Share Estimate Next Year

Profit Margin

Shares Outstanding

12,236,800

Percent Owned by Insiders

0.71%

Percent Owned by Institutions

93.23%

52-Week High

52-Week Low

Technical Indicators for Corbus Pharmaceuticals Holding

50-Day Moving Average

200-Day Moving Average

RSI

51.84

ATR

0.53

Analyst Ratings for Corbus Pharmaceuticals Holding

Strong Buy

Buy

Hold

Sell

Strong Sell

News About Corbus Pharmaceuticals Holding

May 22, 2025, 8:00 AM EST

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. See more.

May 19, 2025, 8:00 AM EST

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. See more.

Mar 28, 2025, 8:00 AM EST

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 See more.

Feb 14, 2025, 7:30 AM EST

Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity observed in both studies Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W See more.